<HashMap><database>GEO</database><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297057</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Multi-omics analysis in EGFR-mutant lung adenocarcinoma</name><description>Using genomic and transcriptomic anaysis, we have identified TP53-GOF mutations as key genomic alterations associated with early resistance to first-line osimertinib therapy in EGFR-mutant NSCLC. Through comprehensive genomic and transcriptomic profiling, we found that TP53-GOF mutations define a biologically distinct subgroup marked by significantly shorter progression-free survival against osimrtinib treatment.</description><dates><publication>2026/05/11</publication></dates><accession>GSE297057</accession><cross_references><GSM>GSM8982761</GSM><GSM>GSM8982762</GSM><GSM>GSM8982760</GSM><GSM>GSM8982747</GSM><GSM>GSM8982748</GSM><GSM>GSM8982745</GSM><GSM>GSM8982746</GSM><GSM>GSM8982765</GSM><GSM>GSM8982743</GSM><GSM>GSM8982766</GSM><GSM>GSM8982744</GSM><GSM>GSM8982763</GSM><GSM>GSM8982741</GSM><GSM>GSM8982742</GSM><GSM>GSM8982764</GSM><GSM>GSM8982750</GSM><GSM>GSM8982751</GSM><GSM>GSM8982758</GSM><GSM>GSM8982759</GSM><GSM>GSM8982756</GSM><GSM>GSM8982757</GSM><GSM>GSM8982754</GSM><GSM>GSM8982755</GSM><GSM>GSM8982752</GSM><GSM>GSM8982753</GSM><GSM>GSM8982749</GSM><GPL>34284</GPL><GSE>297057</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>